Pell Bio-Med Technology Co., Ltd.
Pell Bio-Med Technology Co., Ltd., a biomedical company, engages in the development of cell culture technologies and techniques for therapeutic applications. Its commercial products include good tissue practice laboratory infrastructure, adipose-derived stem cells (ADSC) for regenerative medicine, and CIK and DC-CIK against cancers. The company also develops medicines for various types of cancers… Read more
Pell Bio-Med Technology Co., Ltd. (6949) - Total Liabilities
Latest total liabilities as of September 2025: NT$385.71 Million TWD
Based on the latest financial reports, Pell Bio-Med Technology Co., Ltd. (6949) has total liabilities worth NT$385.71 Million TWD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Pell Bio-Med Technology Co., Ltd. - Total Liabilities Trend (2021–2024)
This chart illustrates how Pell Bio-Med Technology Co., Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Pell Bio-Med Technology Co., Ltd. Competitors by Total Liabilities
The table below lists competitors of Pell Bio-Med Technology Co., Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Gold Royalty Corp.
NYSE MKT:GROY
|
USA | $180.52 Million |
|
Midland States Bancorp Inc
NASDAQ:MSBIP
|
USA | $6.33 Billion |
|
Beijing Hualu Baina Film TV
SHE:300291
|
China | CN¥784.58 Million |
|
Top Resource Conservation Engineering Co Ltd
SHE:300332
|
China | CN¥3.47 Billion |
|
Jiangxi Ganneng Co Ltd
SHE:000899
|
China | CN¥13.23 Billion |
|
MorningStar Partners, L.P.
NYSE:TXO
|
USA | $639.94 Million |
|
MedCap AB (publ)
ST:MCAP
|
Sweden | Skr1.15 Billion |
|
Si-Bone Inc
NASDAQ:SIBN
|
USA | $62.15 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down Pell Bio-Med Technology Co., Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.49 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Pell Bio-Med Technology Co., Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Pell Bio-Med Technology Co., Ltd. (2021–2024)
The table below shows the annual total liabilities of Pell Bio-Med Technology Co., Ltd. from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$458.62 Million | +93.70% |
| 2023-12-31 | NT$236.76 Million | +3.03% |
| 2022-12-31 | NT$229.79 Million | +35.96% |
| 2021-12-31 | NT$169.02 Million | -- |